Department of Breast Surgery, Shiga General Hospital, Moriyama, Japan.
Department of Radiation Therapy, Shiga General Hospital, Moriyama, Japan.
Cancer Rep (Hoboken). 2019 Oct;2(5):e1191. doi: 10.1002/cnr2.1191. Epub 2019 Jul 29.
Radiotherapy is an effective local control therapy for breast cancer. Locoregional control is associated with distant metastasis risk and survival after surgery.
We aimed to evaluate whether Japanese standard postoperative radiotherapy after surgery correlates with disease-free survival (DFS) and overall survival and clarify the characteristics of patients who benefit from it.
This retrospective study included 626 operable breast cancer patients. Tumor characteristics and survival outcomes were compared between patients who received radiotherapy and those who did not. Cox proportional hazard analysis was used to analyze prognostic factors for DFS and perform subgroup analysis. Propensity score matching was used to evaluate the efficacy of radiotherapy using a logistic regression model in patients who received radiotherapy or did not. The median follow-up duration after diagnosis of breast cancer was 63 months. DFS and overall survival were better in the irradiated group (P= .002 and P = .001, respectively). Radiotherapy was more effective for estrogen receptor (ER)-positive disease and for early breast cancer without lymph node metastasis. Multivariate analysis revealed that radiotherapy was a dependent risk factor for recurrence or metastasis.
Radiotherapy prevents distant metastasis and recurrence in early breast cancer patients. In particular, ER-positive, node-negative patients benefit from Japanese standard tangent field radiation.
放射治疗是乳腺癌的一种有效局部控制疗法。局部区域控制与远处转移风险和手术后生存相关。
我们旨在评估日本标准术后放疗与无病生存(DFS)和总生存的相关性,并阐明受益于放疗的患者的特征。
本回顾性研究纳入了 626 例可手术的乳腺癌患者。比较了接受放疗和未接受放疗患者的肿瘤特征和生存结局。采用Cox 比例风险分析对 DFS 的预后因素进行分析,并进行亚组分析。采用逻辑回归模型进行倾向评分匹配,评估接受放疗或未接受放疗患者的放疗疗效。乳腺癌诊断后中位随访时间为 63 个月。放疗组的 DFS 和总生存率更好(P=0.002 和 P=0.001)。放疗对雌激素受体(ER)阳性疾病和无淋巴结转移的早期乳腺癌更有效。多变量分析显示,放疗是复发或转移的独立危险因素。
放疗可预防早期乳腺癌患者的远处转移和复发。特别是,ER 阳性、淋巴结阴性的患者从日本标准切线野放疗中获益。